R. Wayne Rundles, M.D., F.A.C.P.; Harold R. Silberman, M.D., F.A.C.P.; George H. Hitchings, Ph.D.; Gertrude B. Elion, Ph.D.
This content is PDF only. Please click on the PDF icon to access.
A series of pyrazolopyrimidines synthesized some years ago as potential purine antagonists were found to be active in suppressing the growth of bacteria, fungi, tumor cells in culture, and rodent neoplasms. Some of the purine isomers were effective inhibitors of xanthine oxidase in vitro. Two of the most promising compounds, 4-amino- and 4-propylaminopyrazolo (3,4-d)-pyrimidines, were studied clinically as anticancer agents. Their predominant effect was hepatic toxicity.
We have found more recently that a major loss in activity of 6-MP and derivatives in man results from oxidative degradation. The possibility of circumventing this by the administration of 4-hydroxypyrazolo (3,4-d)-pyrimidine (HPP), a
Rundles RW, Silberman HR, Hitchings GH, et al. Effects of Xanthine Oxidase Inhibitor on Clinical Manifestations and Purine Metabolism in Gout.. Ann Intern Med. 1964;60:717–718. doi: 10.7326/0003-4819-60-4-717_2
Download citation file:
Published: Ann Intern Med. 1964;60(4):717-718.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use